Thermo Fisher Scientific TMO has recently been in the limelight for various reasons. Projected as a future success by most analysts, TMO's stock has seen a positive surge and returns of 15% over the past three years. TMO remains a favorite amongst institutional investors who own a majority 89%. To amplify its progress, it has authorized a whopping $5B share repurchase with no timeline. TMO's recent initiatives include receiving FDA approval to identify patients for targeted therapy for non-small cell lung cancer. The clearance for the EXENT system and the opening of a new center in Philly have released encouraging statements about TMO. TMO continues making significant acquisitions, like its recent allotment of $8.88 billion to acquire Clario Holdings, and has also taken strides in the biotech market with initiatives such as launching the multi-parameter molecular assay for rapid beverage quality testing. Despite tangible successes, TMO faced a minor setback in Q2, which saw the shares trading lower for unspecified reasons. TMO has also completed partnerships with OpenAI to accelerate life science breakthroughs.
Thermo Fisher Scientific TMO News Analytics from Sun, 04 May 2025 07:00:00 GMT to Sat, 22 Nov 2025 17:09:27 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 4
